Metastatic Castration-resistant Prostate Cancer Clinical Trials in Fairfax, Virginia

4 studies are recruiting for metastatic castration-resistant prostate cancer in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include partic…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Virginia Cancer Specialists PC, Fairfax, Virginia
    Locations
    33 in total
    Run by
    BioNTech SE

    See if you can join NCT07365995 on ClinicalTrials.gov

  2. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

    The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Virginia, Fairfax, Virginia
    Locations
    10 in total
    Run by
    Flare Therapeutics Inc.

    See if you can join NCT07719361 on ClinicalTrials.gov

  3. A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

    This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Virginia Cancer Specialists (NEXT Virginia), Fairfax, Virginia
    Locations
    19 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT07244341 on ClinicalTrials.gov

  4. ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

    This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. Th…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Virginia Cancer Specialists, Fairfax, Virginia
    Locations
    31 in total
    Run by
    Zenith Epigenetics

    See if you can join NCT04986423 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.